Financials AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-12-10 pm EST			5-day change	1st Jan Change
175.67 ^USD	-0.51%		-3.21%	+13.36%

Dec. 09	AbbVie Reports Durable Results from Mono, Combo Therapy for Blood Cancer	MT
Dec. 09	Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma	CI

Projected Income Statement: AbbVie Inc.

income-statement-evolution-chart ABBVIE-INC

Fiscal Period: Dicembre	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	33,266	45,784	56,122	58,054	54,318	56,038	59,126	63,486
Change	-	37.63%	22.58%	3.44%	-6.44%	3.17%	5.51%	7.37%
EBITDA ¹	17,747	22,642	29,018	30,961	25,545	25,855	28,759	31,751
Change	-	27.58%	28.16%	6.7%	-17.49%	1.22%	11.23%	10.41%
EBIT ¹	15,730	21,976	28,215	30,183	24,793	24,938	27,900	30,920
Change	-	39.71%	28.39%	6.98%	-17.86%	0.58%	11.88%	10.83%
Interest Paid ¹	-1,509	-2,280	-2,384	-2,044	-1,684	-2,186	-2,346	-2,098
Earnings before Tax (EBT) ¹	8,426	3,398	12,989	13,477	6,250	10,190	15,150	16,887
Change	-	-59.67%	282.25%	3.76%	-53.62%	63.04%	48.67%	11.47%
Net income ¹	7,882	4,616	11,542	11,836	4,863	8,100	12,072	14,663
Change	-	-41.44%	150.04%	2.55%	-58.91%	66.56%	49.04%	21.46%
Announcement Date	2/7/20	2/3/21	2/2/22	2/9/23	2/2/24	-	-	-

¹USD in Million

Estimates

Fiscal Period: Dezember	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4
Net sales ¹	8,704	8,619	10,425	12,882	13,858	12,935	13,959	14,342	14,886	13,538	14,583	14,812	15,121	12,225	13,865	13,927	14,301	12,310	14,462	14,460	14,804	13,193	14,880	15,377	15,786
Change	-	-0.98%	20.95%	23.57%	7.58%	-6.66%	7.92%	2.74%	3.79%	-9.06%	7.72%	1.57%	2.09%	-19.15%	13.42%	0.45%	2.69%	-13.92%	17.48%	-0.01%	2.38%	-10.88%	12.79%	3.34%	2.66%
EBITDA ¹	4,394	4,407	5,054	6,459	6,722	6,808	7,145	7,559	7,506	7,156	7,643	8,090	8,072	5,682	6,710	6,706	6,447	5,378	6,342	6,937	7,043	6,055	7,410	7,305	7,374
Change	-	0.3%	14.68%	27.8%	4.07%	1.28%	4.95%	5.79%	-0.7%	-4.66%	6.81%	5.85%	-0.22%	-29.61%	18.09%	-0.06%	-3.86%	-16.58%	17.92%	9.38%	1.53%	-14.03%	22.38%	-1.42%	0.94%
EBIT ¹	3,885	4,292	4,905	6,284	6,495	6,602	6,944	7,336	7,333	6,958	7,440	7,909	7,876	5,503	6,520	6,510	6,260	5,195	6,158	6,746	6,828	6,237	7,104	7,268	7,423
Change	-	10.48%	14.28%	28.11%	3.36%	1.65%	5.18%	5.65%	-0.04%	-5.11%	6.93%	6.3%	-0.42%	-30.13%	18.48%	-0.15%	-3.84%	-17.01%	18.54%	9.55%	1.22%	-8.65%	13.9%	2.31%	2.13%
Charge d'intérêts ¹	-455	-428	-484	-620	-618	-622	-606	-585	-571	-539	-532	-497	-476	-454	-454	-398	-378	-453	-506	-591	-653	-612	-592	-533	-513
Earnings before Tax (EBT) ¹	-	-	-	-	-	-	-	-	-	-	-	-	-	475	2,610	1,953	1,212	1,755	2,146	2,084	3,366	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-	-	-	449.47%	-25.17%	-37.94%	44.8%	22.28%	-2.89%	61.54%	-100%	-	-	-
Net income ¹	2,801	3,010	-738	2,308	36	3,553	766	3,179	4,044	4,490	924	3,949	2,473	239	2,024	1,778	822	1,369	1,370	1,561	2,623	1,418	1,766	1,999	2,282
Change	-	7.46%	-	-	-98.44%	9,769.44%	-78.44%	315.01%	27.21%	11.03%	-79.42%	327.38%	-37.38%	-90.34%	746.86%	-12.15%	-53.77%	66.55%	0.07%	13.94%	68.05%	-45.94%	24.54%	13.19%	14.16%
Announcement Date	2/7/20	5/1/20	7/31/20	10/30/20	2/3/21	4/30/21	7/30/21	10/29/21	2/2/22	4/29/22	7/29/22	10/28/22	2/9/23	4/27/23	7/27/23	10/27/23	2/2/24	4/26/24	7/25/24	10/30/24	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: AbbVie Inc.

Fiscal Period: Dezember	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	26,804	77,607	66,854	54,042	46,571	57,823	48,924	38,465
Change	-	189.54%	-13.86%	-19.16%	-13.82%	24.16%	-15.39%	-21.38%
Announcement Date	2/7/20	2/3/21	2/2/22	2/9/23	2/2/24	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: AbbVie Inc.

Fiscal Period: Dezember	2019	2020	2021	2022	2023	2024	2025	2026
CAPEX ¹	552	798	787	695	777	802.6	821.2	847.4
Change	-	44.57%	-1.38%	-11.69%	11.8%	3.3%	2.31%	3.2%
Free Cash Flow (FCF) ¹	12,772	16,790	21,990	24,248	22,062	17,800	24,900	26,573
Change	-	31.46%	30.97%	10.27%	-9.02%	-19.32%	39.89%	6.72%
Announcement Date	2/7/20	2/3/21	2/2/22	2/9/23	2/2/24	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: AbbVie Inc.

Fiscal Period: Dezember	2019	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	53.35%	49.45%	51.71%	53.33%	47.03%	46.14%	48.64%	50.01%
EBIT Margin (%)	47.29%	48%	50.27%	51.99%	45.64%	44.5%	47.19%	48.7%
EBT Margin (%)	25.33%	7.42%	23.14%	23.21%	11.51%	18.18%	25.62%	26.6%
Net margin (%)	23.69%	10.08%	20.57%	20.39%	8.95%	14.45%	20.42%	23.1%
FCF margin (%)	38.39%	36.67%	39.18%	41.77%	40.62%	31.76%	42.11%	41.86%
FCF / Net Income (%)	162.04%	363.73%	190.52%	204.87%	453.67%	219.76%	206.26%	181.22%
Profitability
ROA	10.62%	3.85%	15.28%	17.24%	14.46%	8.97%	11.15%	13.86%
ROE	-160.36%	188.25%	159.36%	150.62%	143.18%	206.96%	250.75%	249.87%
Financial Health
Leverage (Debt/EBITDA)	1.51x	3.43x	2.3x	1.75x	1.82x	2.24x	1.7x	1.21x
Debt / Free cash flow	2.1x	4.62x	3.04x	2.23x	2.11x	3.25x	1.96x	1.45x
Capital Intensity
CAPEX / Current Assets (%)	1.66%	1.74%	1.4%	1.2%	1.43%	1.43%	1.39%	1.33%
CAPEX / EBITDA (%)	3.11%	3.52%	2.71%	2.24%	3.04%	3.1%	2.86%	2.67%
CAPEX / FCF (%)	4.32%	4.75%	3.58%	2.87%	3.52%	4.51%	3.3%	3.19%
Items per share
Cash flow per share ¹	8.978	10.51	12.82	14.03	12.88	11.26	12.59	14.21
Change	-	17.09%	21.92%	9.45%	-8.18%	-12.56%	11.74%	12.87%
Dividend per Share ¹	4.39	4.84	5.31	5.71	5.99	6.229	6.524	6.826
Change	-	10.25%	9.71%	7.53%	4.9%	3.98%	4.74%	4.63%
Book Value Per Share ¹	-5.507	7.828	8.713	9.743	5.843	4.78	5.918	7.915
Change	-	-242.16%	11.3%	11.82%	-40.03%	-18.19%	23.81%	33.74%
EPS ¹	5.28	2.72	6.45	6.63	2.72	4.773	7.37	8.937
Change	-	-48.48%	137.13%	2.79%	-58.97%	75.49%	54.39%	21.27%
Nbr of stocks (in thousands)	1,478,821	1,765,474	1,767,880	1,767,880	1,765,537	1,767,140	1,767,140	1,767,140
Announcement Date	2/7/20	2/3/21	2/2/22	2/9/23	2/2/24	-	-	-